Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
Shifting the Paradigm of Testosterone and Prostate Cancer: The Saturation Model and the Limits of Androgen-Dependent Growth
European Urology, 02/04/09
Morgentaler A et al. - Evidence from multiple sources indicates there is a limit to the ability of testosterone to stimulate prostate growth. The Saturation Model explains why castration causes prostate cancer to regress, yet testosterone therapy may not cause it to grow more rapidly.
Related Articles
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial
Internet Source, 12/02/09
Relevance Score: 72%
Prostate Cancer Specific Mortality and Gleason 7 Disease Differences in Prostate Cancer Outcomes Between Cases With Gleason 4 + 3 and Gleason 3 + 4 Tumors in a Population Based Cohort
The Journal of Urology, 11/20/09
Relevance Score: 71%
Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection
The Journal of Urology, 11/13/09
Relevance Score: 71%
A prospective study of lifetime physical activity and prostate cancer incidence and mortality
British Journal of Cancer, 11/02/09
Relevance Score: 71%
Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men
The Prostate, 11/02/09
Relevance Score: 71%
Today in Endocrine...keeping you current
Receive free subspecialty "5-minute updates" via email
Oestrogenic mycotoxin exposures and precocious pubertal development
International Journal of Andrology, 12/03/09
Kisspeptin/GPR54 system as potential target for endocrine disruption of reproductive development and function
International Journal of Andrology, 11/13/09
Timetable of effects of testosterone administration to hypogonadal men on variables of sex and mood
The Aging Male, 11/13/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature
European Urology, 12/04/09
Article Search
Sponsor


See Latest Articles


